Over the weekend officials in the Democratic Republic of the Congo (DRC) confirmed 11,000 doses of Johnson & Johnson’s Ebola vaccine (known as the J&J vaccine) had arrived in country, a development that’s been in the works for months as that country battles the second-largest Ebola outbreak in history.
The 11,000 doses are part of 50,000 to be used in a clinical trial evaluating the efficacy of the vaccine in an outbreak setting. The Ad26.ZEBOV, MVA-BN-Filo vaccine will be given to adults and children over the age of 1 in two doses, spaced 2 months apart. The vaccine was developed by Janssen and Bavarian Nordics in 2014 to target the Ebola Zaire strain.
Vaccine use outside of outbreak areas
Read more at CIDRAP…